Cargando…
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of a vaccine protective effect, by translating vaccine immunogenicity in humans to a protective effect, using...
Autores principales: | Roozendaal, Ramon, Hendriks, Jenny, van Effelterre, Thierry, Spiessens, Bart, Dekking, Liesbeth, Solforosi, Laura, Czapska-Casey, Dominika, Bockstal, Viki, Stoop, Jeroen, Splinter, Daniel, Janssen, Sarah, Baelen, Ben van, Verbruggen, Nadia, Serroyen, Jan, Dekeyster, Eline, Volkmann, Ariane, Wollmann, Yvonne, Carrion, Ricardo, Giavedoni, Luis D., Robinson, Cynthia, Leyssen, Maarten, Douoguih, Macaya, Luhn, Kerstin, Pau, Maria Grazia, Sadoff, Jerry, Vandebosch, An, Schuitemaker, Hanneke, Zahn, Roland, Callendret, Benoit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747701/ https://www.ncbi.nlm.nih.gov/pubmed/33335092 http://dx.doi.org/10.1038/s41541-020-00261-9 |
Ejemplares similares
-
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022) -
Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels
por: Tiemessen, Machteld M., et al.
Publicado: (2022) -
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
por: McLean, Chelsea, et al.
Publicado: (2023) -
Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
por: Pasin, Chloé, et al.
Publicado: (2019) -
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
por: Goldstein, Neil, et al.
Publicado: (2020)